Amanda Ferrio
About Amanda Ferrio
Amanda L. Ferrio, 37, is Chief Financial Officer (Principal Financial and Accounting Officer) of NextPlat Corp, appointed effective October 13, 2025, following service as Vice President of Accounting & Finance at Progressive Care LLC (NextPlat’s healthcare subsidiary). She holds a Master of Science and a Bachelor of Science in Accounting and has 15+ years of accounting and finance experience at both Nasdaq-listed and private companies . As CFO, she executed Sarbanes-Oxley Section 302/906 certifications for the Q3 2025 Form 10-Q; management disclosed a previously identified 2024 inventory valuation material weakness had been remediated by September 30, 2025, a governance-positive backdrop as she assumed the role . Company operating context at appointment: Q3 2025 revenue declined year-over-year to $13.8M from $15.4M, with a Q3 net loss of $2.2M (nine-month 2025 revenue $41.5M vs. $49.8M in 2024; nine-month net loss $20.1M), framing pay-for-performance alignment in a turnaround environment .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Progressive Care LLC (NextPlat subsidiary) | Vice President of Accounting & Finance | 2022–2025 | Oversaw accounting/reporting, budgeting/forecasting, and managed SEC filings, providing direct continuity into NextPlat’s CFO role . |
| BBC International, LLC | Controller | Not disclosed | Senior controllership role in consumer products supporting operational finance discipline . |
| Willis Lease Finance Corporation (NASDAQ: WLFC) | Senior Manager, Financial Reporting & Compliance | Not disclosed | Led public company reporting and compliance—relevant to SOX and SEC process rigor . |
| BioMatrix Specialty Pharmacy | Senior Accountant | Not disclosed | Healthcare specialty pharmacy accounting experience, relevant to Progressive Care operations . |
| FedNat (NASDAQ: FNHC) | Senior Accountant | Not disclosed | Public company accounting experience . |
External Roles
No external directorships or committee roles disclosed for Amanda Ferrio .
Fixed Compensation
| Component | Terms | Effective | Notes |
|---|---|---|---|
| Base Salary | $225,000 per year | Oct 13, 2025 | Approved by Board in connection with appointment as CFO . |
| Other Cash Compensation | None disclosed | — | No target bonus or other cash plans disclosed at appointment . |
| Benefits/Perquisites | Not disclosed | — | No additional arrangements disclosed . |
Performance Compensation
| Metric | Weighting | Target | Actual | Payout | Vesting/Notes |
|---|---|---|---|---|---|
| Not disclosed | — | — | — | — | Company states executive bonuses may be used and equity is used broadly, but no specific performance metrics/awards for Ms. Ferrio were disclosed at appointment . |
Equity Ownership & Alignment
| Item | Detail |
|---|---|
| Beneficial Ownership | Form 3 filed October 21, 2025 reported no securities beneficially owned . |
| Ownership as % of Outstanding | 0.0% (0 shares out of 25,963,051 outstanding as of April 28, 2025) . |
| Vested vs. Unvested Shares | None disclosed; no holdings on initial Form 3 . |
| Options/Warrants | None disclosed; no derivative securities on initial Form 3 . |
| Pledging/Hedging | Not disclosed; Company maintains an Insider Trading Policy with pre-clearance and prohibition on trading while in possession of MNPI (policy filed as 2024 10-K exhibit) . |
| Ownership Guidelines | Not disclosed . |
| Clawback Policy | Company adopted an Exchange Act Rule 10D-1 compliant Clawback Policy covering current and former executive officers . |
Employment Terms
| Term | Detail |
|---|---|
| Appointment Date | October 13, 2025 (effective immediately) . |
| Title | Chief Financial Officer (Principal Financial and Accounting Officer) . |
| Employment Agreement | No other material plans, contracts, or arrangements entered into in connection with appointment; only salary change noted . |
| Severance / Change-of-Control | Not disclosed for Ms. Ferrio (no new arrangement at appointment) . |
| Non-Compete / Non-Solicit | Not disclosed . |
Insider Filings, Vesting Schedules, and Selling Pressure
- Initial Statement (Form 3): Filed October 21, 2025; reported no securities beneficially owned .
- Trades (Form 4): None found to date; therefore no disclosed insider selling pressure or scheduled vesting that could create overhang at this time .
- Trading Policy: Insider Trading Policy requires pre-clearance for designated employees and prohibits trading on MNPI, mitigating event-driven trading risks .
Performance & Track Record Signals
- SOX Certifications: Signed Section 302 and 906 certifications for Q3 2025 10-Q as CFO, indicating responsibility over disclosure controls and financial reporting .
- Controls Remediation: Company remedied a fiscal 2024 inventory valuation material weakness by Q3 2025 via NRV policy/process enhancements and senior review; this represents a strengthening of financial controls environment coincident with her assumption of CFO leadership .
- Operating Backdrop at Appointment: Q3 2025 revenue $13.8M (vs. $15.4M in Q3 2024) and net loss of $2.2M; nine-month 2025 revenue $41.5M (vs. $49.8M in 2024) and net loss of $20.1M, underscoring turnaround and cost-discipline imperatives for incentive design .
Governance and Compensation Committee Context
- Compensation Committee: Independent directors Hector Delgado (Chair), Louis Cusimano, and Anthony Armas oversee executive compensation and administer equity plans .
- Equity Plans: Company utilizes the Amended & Restated 2020 Plan and 2021 Incentive Award Plan for RSUs/options and performance awards, with change-in-control and repricing restrictions set by plan terms; no individual awards for Ms. Ferrio disclosed at appointment .
Investment Implications
- Pay-for-performance alignment: With only base salary disclosed ($225k) and no equity or bonus plan specified at appointment, Ms. Ferrio’s compensation currently has limited direct performance linkage; investors should watch for subsequent equity grants or bonus metrics to align incentives with margin improvement, cash generation, and control rigor .
- Selling pressure risk: Initial Form 3 shows zero holdings and no Form 4 activity, implying minimal near-term insider selling overhang from her account; monitor for new grants and associated vesting schedules that could create future supply .
- Control environment: The recently remediated inventory valuation material weakness and her immediate SOX certifications point to a focus on financial discipline; further enhancements to disclosure controls and timely reporting under her tenure would be a positive execution signal .
- Retention and contract economics: No severance, change-in-control, or long-term equity package disclosed at appointment; absence of retention features may limit golden handcuff effects but also reduces shareholder overhang. Future filings (proxy/8-K) should be monitored for any employment agreement or equity grants to assess alignment and retention .
- Strategic fit: Her combined healthcare operations finance and public-company reporting experience (Progressive Care, WLFC, FNHC) matches NextPlat’s hybrid healthcare/e-commerce footprint and could be accretive to execution on refocusing plans, as highlighted in the Company’s appointment announcement .